A miracle cancer drug in the era of social media: A survey of Brazilian oncologists' opinions and experience with phosphoethanolamine

Juliana Florinda M RêGo, Gilberto Lopes, Rachel P. Riechelmann, Cinthya Sternberg, Claudio Ferrari, Gustavo Fernandes

Research output: Research - peer-reviewReview article

Abstract

Introduction: Patients who are treating cancer have often used alternative therapies. In the internet era, information can be broadcasted widely, and this happened with phosphoethanolamine in Brazil, where this substance was claimed by the population to be the "cure for cancer." Method: This is a cross-sectional study developed by the Brazilian Society of Clinical Oncology (SBOC). An objectively structured questionnaire was sent by e-mail and SMS to active MDs members of the SBOC. Descriptive statistics was used to evaluate the data. Statistical signifcance between the variables was tested by Pearson's Chi-squared test (p<0.05 was considered signifcance). Results: The survey was sent to 1,072 oncologists, and 398 (37.1%) answered at least part of it. One hundred and ffteen (28.9%) had followed patients who had used phosphoethanolamine. Among these, 14 (12.2%) observed adverse events and four (3.5%) attributed clinical beneft to the substance. Most of the oncologists (n=331; 83.2%) believe that it should only be used as part of a clinical trial protocol. Most physicians did not recommend this drug to their patients (n=311; 78.1%). Oncologists in Southeast, South and Midwest Brazil were more likely to have patients taking the drug compared to the Northern and Northeastern regions. Conclusion: This is the frst survey to assess the opinion and experience of oncologists about this alternative therapy. Most oncologists in Brazil do not believe that synthetic phosphoethanolamine is active in cancer treatment, do not recommend its use without proper evaluation, and state that it should only be available to patients in the context of clinical trials.

LanguageEnglish (US)
Pages70-77
Number of pages8
JournalRevista da Associacao Medica Brasileira
Volume63
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Social Media
Pharmaceutical Preparations
Neoplasms
Surveys and Questionnaires
phosphorylethanolamine
Oncologists
Brazil
Complementary Therapies
Clinical Protocols
Clinical Trials
Medical Oncology
Postal Service
Internet
Cross-Sectional Studies
Physicians
Population
Therapeutics

Keywords

  • Alternative therapies
  • Brazil
  • Cancer
  • Phosphoethanolamine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A miracle cancer drug in the era of social media : A survey of Brazilian oncologists' opinions and experience with phosphoethanolamine. / RêGo, Juliana Florinda M; Lopes, Gilberto; Riechelmann, Rachel P.; Sternberg, Cinthya; Ferrari, Claudio; Fernandes, Gustavo.

In: Revista da Associacao Medica Brasileira, Vol. 63, No. 1, 01.01.2017, p. 70-77.

Research output: Research - peer-reviewReview article

RêGo, Juliana Florinda M ; Lopes, Gilberto ; Riechelmann, Rachel P. ; Sternberg, Cinthya ; Ferrari, Claudio ; Fernandes, Gustavo. / A miracle cancer drug in the era of social media : A survey of Brazilian oncologists' opinions and experience with phosphoethanolamine. In: Revista da Associacao Medica Brasileira. 2017 ; Vol. 63, No. 1. pp. 70-77
@article{ef1d7a1ad70b486d99a50738d28eba43,
title = "A miracle cancer drug in the era of social media: A survey of Brazilian oncologists' opinions and experience with phosphoethanolamine",
abstract = "Introduction: Patients who are treating cancer have often used alternative therapies. In the internet era, information can be broadcasted widely, and this happened with phosphoethanolamine in Brazil, where this substance was claimed by the population to be the {"}cure for cancer.{"} Method: This is a cross-sectional study developed by the Brazilian Society of Clinical Oncology (SBOC). An objectively structured questionnaire was sent by e-mail and SMS to active MDs members of the SBOC. Descriptive statistics was used to evaluate the data. Statistical signifcance between the variables was tested by Pearson's Chi-squared test (p<0.05 was considered signifcance). Results: The survey was sent to 1,072 oncologists, and 398 (37.1%) answered at least part of it. One hundred and ffteen (28.9%) had followed patients who had used phosphoethanolamine. Among these, 14 (12.2%) observed adverse events and four (3.5%) attributed clinical beneft to the substance. Most of the oncologists (n=331; 83.2%) believe that it should only be used as part of a clinical trial protocol. Most physicians did not recommend this drug to their patients (n=311; 78.1%). Oncologists in Southeast, South and Midwest Brazil were more likely to have patients taking the drug compared to the Northern and Northeastern regions. Conclusion: This is the frst survey to assess the opinion and experience of oncologists about this alternative therapy. Most oncologists in Brazil do not believe that synthetic phosphoethanolamine is active in cancer treatment, do not recommend its use without proper evaluation, and state that it should only be available to patients in the context of clinical trials.",
keywords = "Alternative therapies, Brazil, Cancer, Phosphoethanolamine",
author = "RêGo, {Juliana Florinda M} and Gilberto Lopes and Riechelmann, {Rachel P.} and Cinthya Sternberg and Claudio Ferrari and Gustavo Fernandes",
year = "2017",
month = "1",
doi = "10.1590/1806-9282.63.01.70",
volume = "63",
pages = "70--77",
journal = "Revista da Associacao Medica Brasileira",
issn = "0104-4230",
publisher = "Associacao Medica Brasileira",
number = "1",

}

TY - JOUR

T1 - A miracle cancer drug in the era of social media

T2 - Revista da Associacao Medica Brasileira

AU - RêGo,Juliana Florinda M

AU - Lopes,Gilberto

AU - Riechelmann,Rachel P.

AU - Sternberg,Cinthya

AU - Ferrari,Claudio

AU - Fernandes,Gustavo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Patients who are treating cancer have often used alternative therapies. In the internet era, information can be broadcasted widely, and this happened with phosphoethanolamine in Brazil, where this substance was claimed by the population to be the "cure for cancer." Method: This is a cross-sectional study developed by the Brazilian Society of Clinical Oncology (SBOC). An objectively structured questionnaire was sent by e-mail and SMS to active MDs members of the SBOC. Descriptive statistics was used to evaluate the data. Statistical signifcance between the variables was tested by Pearson's Chi-squared test (p<0.05 was considered signifcance). Results: The survey was sent to 1,072 oncologists, and 398 (37.1%) answered at least part of it. One hundred and ffteen (28.9%) had followed patients who had used phosphoethanolamine. Among these, 14 (12.2%) observed adverse events and four (3.5%) attributed clinical beneft to the substance. Most of the oncologists (n=331; 83.2%) believe that it should only be used as part of a clinical trial protocol. Most physicians did not recommend this drug to their patients (n=311; 78.1%). Oncologists in Southeast, South and Midwest Brazil were more likely to have patients taking the drug compared to the Northern and Northeastern regions. Conclusion: This is the frst survey to assess the opinion and experience of oncologists about this alternative therapy. Most oncologists in Brazil do not believe that synthetic phosphoethanolamine is active in cancer treatment, do not recommend its use without proper evaluation, and state that it should only be available to patients in the context of clinical trials.

AB - Introduction: Patients who are treating cancer have often used alternative therapies. In the internet era, information can be broadcasted widely, and this happened with phosphoethanolamine in Brazil, where this substance was claimed by the population to be the "cure for cancer." Method: This is a cross-sectional study developed by the Brazilian Society of Clinical Oncology (SBOC). An objectively structured questionnaire was sent by e-mail and SMS to active MDs members of the SBOC. Descriptive statistics was used to evaluate the data. Statistical signifcance between the variables was tested by Pearson's Chi-squared test (p<0.05 was considered signifcance). Results: The survey was sent to 1,072 oncologists, and 398 (37.1%) answered at least part of it. One hundred and ffteen (28.9%) had followed patients who had used phosphoethanolamine. Among these, 14 (12.2%) observed adverse events and four (3.5%) attributed clinical beneft to the substance. Most of the oncologists (n=331; 83.2%) believe that it should only be used as part of a clinical trial protocol. Most physicians did not recommend this drug to their patients (n=311; 78.1%). Oncologists in Southeast, South and Midwest Brazil were more likely to have patients taking the drug compared to the Northern and Northeastern regions. Conclusion: This is the frst survey to assess the opinion and experience of oncologists about this alternative therapy. Most oncologists in Brazil do not believe that synthetic phosphoethanolamine is active in cancer treatment, do not recommend its use without proper evaluation, and state that it should only be available to patients in the context of clinical trials.

KW - Alternative therapies

KW - Brazil

KW - Cancer

KW - Phosphoethanolamine

UR - http://www.scopus.com/inward/record.url?scp=85016052158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016052158&partnerID=8YFLogxK

U2 - 10.1590/1806-9282.63.01.70

DO - 10.1590/1806-9282.63.01.70

M3 - Review article

VL - 63

SP - 70

EP - 77

JO - Revista da Associacao Medica Brasileira

JF - Revista da Associacao Medica Brasileira

SN - 0104-4230

IS - 1

ER -